DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Hydrea (Hydroxyurea) - Published Studies

 
 



Hydrea Related Published Studies

Well-designed clinical trials related to Hydrea (Hydroxyurea)

Hydroxyurea and growth in young children with sickle cell disease. [2014]

Immunologic effects of hydroxyurea in sickle cell anemia. [2014]

Impact of hydroxyurea on clinical events in the BABY HUG trial. [2012]

Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. [2012]

Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. [2012]

Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. [2011.12.01]

Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: Results from the BABY-HUG phase III clinical trial. [2011.10.19]

The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. [2011.05]

Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy. [2010.12.14]

Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. [2010.12]

The impact of hydroxyurea on career and employment of patients with sickle cell anemia. [2010.11]

Hydroxyurea and Acute Painful Crises in Sickle Cell Anemia: Effects on Hospital Length of Stay and Opioid Utilization During Hospitalization, Outpatient Acute Care Contacts, and at Home. [2010.09.21]

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. [2010.06]

The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. [2010.02]

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. [2010.02]

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. [2010.01.01]

Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy. [2010]

The impact of hydroxyurea on career and employment of patients with sickle cell anemia. [2010]

The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. [2010]

Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. [2009.10]

The pediatric hydroxyurea phase III clinical trial (BABY HUG): Challenges of study design. [2009.09.03]

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. [2009.08.06]

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. [2008.12]

The effect of hydroxyurea in spinal muscular atrophy cells and patients. [2008.05.15]

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. [2007.12]

Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients. [2007.11]

Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. [2007.07.01]

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. [2007.03.15]

Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial. [2007]

Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease. [2006.12]

Hydroxyurea and sickle cell anemia: effect on quality of life. [2006.08.31]

The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse). [2006.06]

Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms. [2005.07.22]

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. [2005.07.07]

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens. [2005.04.08]

Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. [2005.04]

Effect of adjunct hydroxyurea on helper T cell immunity in HIV type 1-infected patients with virological suppression. [2004.08]

Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects. [2004.03.05]

A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART). [2004.03]

Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival. [2004]

Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix. [2004]

Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. [2003.08]

Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. [2003.05]

A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). [2003.05]

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. [2003.04.02]

Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. [2002.12.06]

The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations. [2002.07]

Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296. [2002.05]

Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection. [2002.04.01]

Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate. [2001.12.01]

Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. [2001.07.27]

Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study. [2000.09.29]

Combination therapy with hydroxyurea versus without hydroxyurea as first line treatment options for antiretroviral-naive patients. [2000.09]

Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. [2000.09]

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. [2000.05]

A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study. [2000.04]

Hydroxyurea for HIV infection. [1998.04]

[Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age] [1998.03]

Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study. [1998]

Well-designed clinical trials possibly related to Hydrea (Hydroxyurea)

Front-line therapy in polycythemia vera and essential thrombocythemia. [2012]

Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. [2012]

Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. [2011.06]

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). [2011.05.14]

Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. [2011.04.15]

The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. [2011.03]

Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. [2011.02]

Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. [2011]

The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. [2011]

Recruitment of infants with sickle cell anemia to a Phase III trial: data from the BABY HUG study. [2010.11]

Recruitment of infants with sickle cell anemia to a Phase III trial: Data from the BABY HUG study. [2010.08.24]

Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. [2010.05]

Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. [2010.01]

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. [2009.06.20]

Hematopoietic stem cell transplantation for children with sickle cell disease. [2009.01.21]

Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. [2008.12.01]

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. [2008.02.20]

Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. [2008.02.01]

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. [2008.01.01]

Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. [2007.08]

Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. [2007.06]

The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study. [2007.05]

Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. [2007]

Phase III double-blind randomized trial of radiation therapy for stage IIIb cervical cancer in combination with low- or high-dose Z-100: treatment with immunomodulator, more is not better. [2006.06]

Effects of 5-lipoxygenase inhibitor zileuton on airway responses to inhaled swine house dust in healthy subjects. [2006.02]

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. [2005.12.03]

Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. [2005.08]

Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. [2005.06]

[Comparison of therapeutic effects of low-dose versus high-dose interferon alpha-2b treatment on chronic myelocytic leukemia: a prospective randomized study] [2005.05.25]

The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude. [2005.02]

Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. [2004.07.15]

Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. [2004.06.15]

Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection. [2004.06.01]

Sickle cell disease: primary stroke prevention. [2004.06]

Suppression of leukotriene B4 generation by ex-vivo neutrophils isolated from asthma patients on dietary supplementation with gammalinolenic acid-containing borage oil: possible implication in asthma. [2004.03]

Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions. [2004.02]

Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial. [2003.12]

A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses. [2003.12]

Combined-modality therapy of locally advanced cervical cancer. [2003.05.15]

Divergent nitric oxide bioavailability in men and women with sickle cell disease. [2003.01.21]

A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. [2003.01.03]

What is the standard treatment in essential thrombocythemia. [2002.08]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017